The Economics Orphan Drugs: Supply Chains, Data Security, and Transparency

? Orphan drugs are medicinal products developed specifically to treat diseases which, by definition, affect only a small portion of the population. Many of them are called orphan diseases that are serious, life-threatening and chronic, including cystic fibrosis, Huntington's disease or rare cancers.

? Economics challenges unique to orphan drugs: -The development and distribution of orphan drugs present several economic challenges that differentiate them from traditional pharmaceuticals. These challenges stem primarily from the small patient populations they serve and the complexities of developing treatments for rare diseases.

• Scope of the Research analysing the economics of orphan drugs

1) Supply Chains:-

Production and distribution obstacles: - The limited patient populations for rare diseases, often scattered across various locations, create challenges in manufacturing and logistical aspects.

Cost Analysis: -Evaluating production, transportation and storage costs for bottlenecks.

Sustaining: - Securing continued supply while minimising threats of shortages or disruption.

2) Data Security: -

Patient Privacy: -Protecting sensitive patient data in compliance with regulations such as GDPR and HIPAA.

Industrial Data: -This information is about protecting secret formulas, production processes and clinical trials from hackers.

The Role of Technology: -Analysing blockchain and artificial intelligence tools for data security.

3)Transparency: -

Pricing Models: -Why we are paying so much for drugs, and why nobody seems to know how much they cost.

Regulatory Oversight: -Examining the compliance and reporting regimes in different jurisdictions.

Provide information to patients, regulators, manufacturers and healthcare providers to build trust with stakeholders.

Background on Orphan Drugs

1) Regulatory Framework: -A regulatory framework is a set of rules, regulations, and laws that govern how a sector or industry operates. It is known as a regulatory framework.

India: -Defines orphan drugs as drugs that treat conditions affecting no more than 500,000 people. The Central Drugs Control Standards Organization (CDSCO) can waive the need for local clinical trials, and clinical trial sponsors can request a faster approval process.

United States: -a disease as rare if it affects fewer than 200,000 people. The Orphan Drug Act (ODA) of 1983 incentivizes pharmaceutical companies to invest in orphan drugs.

European Union: -Defines a disease as rare if it affects fewer than 1 in 10,000 people.

2)What Is Orphan Drugs?

Orphan drugs are used to treat, prevent, or diagnose a rare disease or condition.it is also known as orphan drugs.

3)The Criteria for Orphan Designation: -

?A medicine, including vaccines or in vivo diagnostic agents, may qualify for orphan drug designation if it meets all the criteria outlined in regulation 16J of the Therapeutic Goods Regulations 1990.

?Along with the standard orphan designation pathway, there is an additional pathway for medicines in new dosage forms.

?This pathway aims to encourage sponsors to register medicines on the Australian Register of Therapeutic Goods (ARTG) by offering a TGA fee waiver for new dosage forms that would otherwise not be financially viable.

4)Overview of Regulatory Incentives

•Tax Credits: -Tax credits can cover up to 50% of research and development costs in the United States.

•User Fee Waivers: -The Prescription Drug User Fee is waived for orphan drugs.

•Market Exclusivity: -After approval, orphan drugs are granted market exclusivity for up to seven years.

•Financial Support: -The Office of Orphan Products Development (OOPD) provides financial assistance to researchers who apply for orphan drug designation.

•Protocol Guidance: - Protocol assistance is available to help with the development of orphan drugs.

•Priority Review Vouchers: - Vouchers are available for rare paediatric and tropical diseases.

•Grants: -Grants are available to support the clinical development of orphan drugs.

Market Dynamics

1) Rising Prevalence of Rare Diseases: -Rare Diseases are becoming more common as diagnostics improve and awareness grows. This increased visibility results in a larger patient pool in need of treatment, which drives up demand for orphan medications.

2) Unmet Medical Needs and Limited Treatment Options: -Many uncommon diseases do not have viable treatments, resulting in a huge unmet medical demand. Orphan medications provide an opportunity to close this gap by encouraging pharmaceutical corporations to engage in research and development.

3) Technological advancements and innovation:- Breakthroughs in gene therapy, personalised medicine, and biological drug development are making way for more targeted and effective orphan medications. These breakthroughs have the potential to lead to curative treatments and better patient outcomes, which will drive market expansion even further.

4) Growing Public and Patient Advocacy: -Medical developments and strong patient advocacy groups have contributed to increased awareness of rare diseases. These organisations create public awareness, lobby for government funding, and promote research and development, thus moving the orphan medicine industry ahead.

5) Focus on Orphan Drugs in Pharmaceutical Companies: - Pharmaceutical corporations are allocating more resources to orphan medication development, recognizing the business opportunity and ethical obligation. This not only benefits patients with uncommon diseases,but it also provides firms with the opportunity to earn huge returns on investment.

6) Growing financing Opportunities: - Increased government financing for research grants, as well as public-private partnerships focusing on rare diseases, are making it easier to produce orphan drugs. This financial support enables early-stage research and clinical trials, eventually leading to a broader range of orphan drug choices.

?Orphan Drugs Market Overview:- Orphan drugs market size was valued at USD 196.60 billion in 2023 and is projected to grow from USD 219.54 Billion in 2024 to USD 480.27 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.08% during the forecast period (2024-2032). The rising prevalence of rare diseases, growing investment. in research and development of orphan drugs.